(Total Views: 394)
Posted On: 02/16/2021 1:39:24 PM
Post# of 145247
CTMedic - Right, that's why maybe the trial analysts and the FDA are taking the time to evaluate the post-28 day mortality rates for both arms. In looking at the chart 5 from the aviptadil trial results, looks like the 28-42 day mortality represents the lion's share of the 28-77 day rate.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)